CITATION REPORT List of articles citing

Effect of tipranavir/ritonavir combination on the pharmacokinetics of tadalafil in healthy volunteers

DOI: 10.1177/0091270010379808 Journal of Clinical Pharmacology, 2011, 51, 1071-8.

Source: https://exaly.com/paper-pdf/49980922/citation-report.pdf

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
18	Simple and sensitive liquid chromatography-tandem mass spectrometry methods for quantification of tadalafil in rat plasma: application to pharmacokinetic study in rats. <i>Archives of Pharmacal Research</i> , 2013 , 36, 457-63	6.1	8
17	The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases. <i>Global Cardiology Science & Practice</i> , 2014 , 2014, 257-90	0.7	10
16	Antiviral drugs. Side Effects of Drugs Annual, 2014 , 503-550	0.2	O
15	HIV-associated pulmonary arterial hypertension: from bedside to the future. <i>European Journal of Clinical Investigation</i> , 2015 , 45, 515-28	4.6	25
14	Drug interactions between antiretrovirals and drugs used to treat benign prostatic hyperplasia/lower urinary tract symptoms. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016 , 12, 1211-24	5.5	4
13	Pharmacological treatment of HIV-associated pulmonary hypertension. <i>Expert Review of Clinical Pharmacology</i> , 2016 , 9, 715-25	3.8	5
12	HIV-associated pulmonary hypertension. Current Opinion in HIV and AIDS, 2017, 12, 566-571	4.2	16
11	Effect of Ticagrelor, a Cytochrome P450 3A4 Inhibitor, on the Pharmacokinetics of Tadalafil in Rats. <i>Pharmaceutics</i> , 2019 , 11,	6.4	3
10	Prescribing issues in elderly individuals living with HIV. <i>Expert Review of Clinical Pharmacology</i> , 2019 , 12, 643-659	3.8	11
9	Pulmonary Hypertension in HIV. Canadian Journal of Cardiology, 2019, 35, 288-298	3.8	14
8	Advances in the diagnosis and treatment of HIV-associated pulmonary arterial hypertension. <i>Expert Opinion on Orphan Drugs</i> , 2020 , 8, 169-177	1.1	
7	Lopinavir-Ritonavir in SARS-CoV-2 Infection and Drug-Drug Interactions with Cardioactive Medications. <i>Cardiovascular Drugs and Therapy</i> , 2021 , 35, 427-440	3.9	9
6	Phosphodiesterase type V inhibitors. 2016 , 734-742		
5	Pharmacokinetic drug-drug interaction and their implication in clinical management. <i>Journal of Research in Medical Sciences</i> , 2013 , 18, 601-10	1.6	141
4	Pulmonary Arterial Hypertension in Patients Infected with the Human Immunodeficiency Virus. <i>Cardiology Clinics</i> , 2022 , 40, 45-54	2.5	1
3	2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. 2200879		18
2	2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.		58

Human Immunodeficiency Virus Associated Pulmonary Arterial Hypertension. **2022**, 21, 115-122

О